Article references (8 references )


  1. Zaraa I, Sellami A, Bouguerra C, Sellami MK, Chelly I, Zitouna M et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study: pemphigus vegetans. J Eur Acad Dermatol Venereol. 2011;25(10):1160-1167. PubMed | Google Scholar

  2. Dhamija A, Kothiwala R, Meherda A, D'souza P. Pemphigus vegetans: an unusual presentation. Indian Dermatol Online J. 2012;3(3):193. PubMed

  3. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003 Nov;149(5):926-37. PubMed | Google Scholar

  4. Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168-17. PubMed | Google Scholar

  5. Joly P, Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S. Recommandations des centres de référence des maladies bulleuses auto-immunes pour le diagnostic et la prise en charge du pemphigus. Ann Dermatol Vénéréologie. 2011;138(3):252-258. PubMed

  6. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2008;6(5):366-373. PubMed | Google Scholar

  7. Enk A, European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol EJD. 2009;19(1):90-98. PubMed | Google Scholar

  8. Ruiz-Villaverde R, Galán-Gutierrez M, Sanchez-Cano D. Treatment of pemphigus vegetans to rituximab refractory to conventional therapy. Acta Dermatovenerol Croat ADC. 2014;22(3):221-223. PubMed | Google Scholar